
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is comparing atezolizumab and cabozantinib with docetaxel for people with non small cell lung cancer.
It is for people whose cancer has spread elsewhere in the body. This is advanced lung cancer.
Doctors are looking for ways to improve treatment for people with advanced non small cell lung cancer (NSCLC).
In this trial they are looking at a new combination of drugs. This includes 2 drugs called atezolizumab and cabozantinib.
Atezolizumab is a drug you may have to treat advanced NSCLC that has got worse. It is an immunotherapy. It helps the to find and kill cancer cells.
Cabozantinib is a type of cancer growth blocker. It stops signals that cancer cells use to divide and grow. It is a new drug for lung cancer. Researchers want to find out if adding it to atezolizumab slows cancer growth.
Docetaxel is a chemotherapy drug. It is a usual treatment for NSCLC that has spread.
In this trial some people have atezolizumab and cabozantinib. And some people have docetaxel.
The main aims of the trial are to:
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You can’t join the trial if the following apply. You:
Other
You can’t take part if the following apply. You:
This is a phase 3 trial. It is taking place worldwide. The researchers need 350 people to take part including at least 15 from the UK.
It is randomised trial. You are put into a group by a computer. Neither you nor your doctor will be able to decide which group you are in. There are 2 treatment groups. You have 1 of the following:
You have treatment for as long as it is working and the side effects aren’t too bad.
Atezolizumab and cabozantinib
You have atezolizumab as a drip into a vein. You have it once every 3 weeks.
Cabozantinib is a tablet. You take them once a day, every day.
Docetaxel
You have docetaxel as a drip into a vein. You have it once every 3 weeks.
Blood and tissue samples
The researchers ask you to give an extra tissue sample. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
The researchers use the samples to look for differences in substances called . This can help researchers to work out why treatment might work for some people and not for others.
You need to agree to give most of the samples in the trial. There are a few you don’t need to agree to if you don’t want to. The team can let you know more about this.
You see a doctor and have some tests before you can take part in the trial. These include:
You may also need to give a tissue sample ().
During treatment you see the doctor every 3 weeks for a check up and blood tests.
You have a CT or MRI scan:
When you finish treatment you see the doctor 1 month later. If your cancer hasn’t got worse you continue to have scans every 6 to 9 weeks. You have a final scan after about 6 weeks if your cancer gets worse.
Follow up
The team follow you up every 3 months when you finish treatment. You might see them at a routine hospital appointment or they may call you to see how you are getting on.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Atezolizumab can affect the immune system. It may cause inflammation in different parts of the body which can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening. If you have any of these side effects, you should tell the doctor or nurse as soon as possible. You should tell them you are on or have been on an immunotherapy. |
The most common side effects of atezolizumab are:
The most common side effects of cabozantinib include:
We have information about the side effects of:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tom Newsom-Davis
Chugai Pharmaceutical Co Ltd
Exelixis
F. Hoffmann La Roche
Genentech Inc
Ipsen Pharma SAS
Takeda Pharmaceutical Co Ltd
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”